EC approves Sobi-ADC's Zynlonta for diffuse large B-cell lymphoma
The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.
Anders Ullman Sobi Research Development Committee For Medicinal Products Human European Union European Medicines Agency European Commission
Source: pharmaceutical-technology.com